Improvement in health related quality of life in infliximab-treated moderate-to-severe active ulcerative colitis patients
B E Sands(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Paul Rutgeerts(KU Leuven), M Bala, Simin Yan, S. Hanauer(University of Illinois Chicago), B. Feagan, D. Eisenberg, Jewel Johanns(Johnson & Johnson (United States)), William J. Sandborn(University of San Diego)
Cited by 1
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k